Brought to you by 
RiboTargets closes $47mm private round
27 Apr 2021
Executive Summary
RiboTargets (anti-infectives and oncology drugs) completed a third round private placement, selling $47mm (UK32mm) of its equity to lead participant JP Morgan and OrbiMed Advisors (both new investors) and returning investors Apax Partners, 3i PLC, Advent Venture Partners, NIB Capital, and Quester.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
RiboTargets closes $47mm private round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice